本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Bioxcel Therapeutics Inc.

4.23
+0.440011.61%
盘前3.94-0.2900-6.86%08:34 EDT
成交量:247.99万
成交额:1,003.39万
市值:6,157.48万
市盈率:-0.34
高:4.29
开:3.76
低:3.76
收:3.79
52周最高:13.36
52周最低:1.17
股本:1,455.67万
流通股本:551.26万
量比:0.93
换手率:44.99%
股息:- -
股息率:- -
每股收益(TTM):-12.2842
每股收益(LYR):-23.5105
净资产收益率:-1766.94%
总资产收益率:-68.72%
市净率:-0.57
市盈率(LYR):-0.18

数据加载中...

2024/06/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/06/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/06/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/06/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/06/12

重要事件披露

Form 8-K - Current report
2024/06/06

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/06/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/05/09

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/09

重要事件披露

Form 8-K - Current report
2024/04/22

重要事件披露

Form 8-K - Current report
2024/04/10

重要事件披露

Form 8-K - Current report
2024/04/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/05

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/03

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/25

重要事件披露

Form 8-K - Current report
2024/03/22

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]